Condition: Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract Cancer · Sponsor: AstraZeneca
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Orange, California, United States | Recruiting |
| Research Site | Palo Alto, California, United States | Recruiting |
| Research Site | Santa Rosa, California, United States | Recruiting |
| Research Site | Louisville, Kentucky, United States | Recruiting |
| Research Site | Commack, New York, United States | Recruiting |
| Research Site | Providence, Rhode Island, United States | Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Melbourne, Australia | Recruiting |
| Research Site | Murdoch, Australia | Recruiting |
| Research Site | Randwick, Australia | Recruiting |
| Research Site | Kingston, Ontario, Canada | Withdrawn |
| Research Site | Toronto, Ontario, Canada | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06219941